Emm, the UK-based pioneer in biowearable technology, announces it has raised £6.8 million in an oversubscribed seed funding round, to bring the world’s first smart menstrual cup and connected app to market. Creating a new category of “smart menstrual care”, Emm will equip users to understand their individual menstrual baseline and track key metrics for personalised, actionable insights into their menstrual health.
The round was led by Lunar Ventures, with additional participation from the Labcorp Venture Fund, Tiny VC, Blue Lion Global, Alumni Ventures (investor in Oura & Levels), and a network of high-profile angels, including Amar Shah (co-founder of Wayve), Vivek Garipalli (founder of Clover Health and Wormhole Capital), and Harpreet Rai (former CEO, Oura). Emm has also received non-dilutive funding, including grants that support innovation in women’s health technology.
This funding will support Emm in bringing this first-of-its-kind product to market transforming how people experience and understand their cycles, and by extension, their bodies. It will also accelerate the pathway to further clinical product development, as the business moves to transform the research, diagnosis and treatment of reproductive and menstrual health conditions.
Despite affecting half the global population, menstrual and women’s reproductive health remain among the most under-served areas in healthcare. 1 in 3 women will experience severe menstrual or reproductive health symptoms in their lifetime, yet both clinicians and individuals lack reliable tools for baseline measurement and tracking until now.
Emm is addressing this gap with a breakthrough wearable device that objectively measures menstrual flow volume and tracks key cycle metrics, such as duration, frequency and regularity – offering users accurate, personalised health insights for the first time, together with an absolute commitment to privacy.
Developed over five years with thousands of design iterations and extended user testing, the non-intrusive cup integrates medical-grade silicone with ultra-thin advanced sensor technology. The accompanying connected app automatically collates baseline data over time, allowing users to identify and track patterns, understand their own biology and have more effective conversations with healthcare professionals about their symptoms, in just three cycles.
Jenny Button founded Emm in 2020 to transform outcomes in women’s health. The company’s board is chaired by Grace E. Colón, PhD; a biotech leader with nearly 30 years’ experience across biopharma, genomics, and healthcare, currently serving on multiple corporate and nonprofit boards including Voyager Therapeutics, MIT, and BIO.
Emm will launch to consumers in the UK in early 2026, with other markets to follow. The waitlist for new subscribers is now open via the Emm website.
